Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Journal of Neurology, Neurosurgery, and Psychiatry|August 31, 2019
Consistent control of disease activity with fingolimod versus IFN β-1a in paediatric-onset multiple sclerosis: further insights from PARADIG<i>MS</i>Kumaran Deiva, Peter Huppke, Brenda Banwell, et al.The Journal of Nutrition|January 21, 2006
Pyrroloquinoline quinone modulates mitochondrial quantity and function in miceTracy Stites, David Storms, Kathryn Bauerly, et al.Neurology|March 27, 2015
Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosisJens Kuhle, Giulio Disanto, Johannes Lorscheider, et al.Journal of Neurology, Neurosurgery, and Psychiatry|November 30, 2021
Two-year efficacy and safety of erenumab in participants with episodic migraine and 2-4 prior preventive treatment failures: results from the LIBERTY studyMichel Dominique Ferrari, Uwe Reuter, Peter J Goadsby, et al.Journal of Neurology, Neurosurgery, and Psychiatry|June 27, 2015
Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS studyJeffrey A Cohen, Bhupendra Khatri, Frederik Barkhof, et al.The Lancet. Neurology|May 17, 2011
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS studyBhupendra Khatri, Frederik Barkhof, Giancarlo Comi, et al.JAMA Neurology|March 25, 2024
Early Use of Erenumab vs Nonspecific Oral Migraine Preventives: The APPRAISE Randomized Clinical TrialPatricia Pozo-Rosich, David Dolezil, Koen Paemeleire, et al.Neurology|April 26, 2024
Efficacy and Safety of Erenumab in Participants With Episodic Migraine in Whom 2-4 Prior Preventive Treatments Had Failed: LIBERTY 3-Year StudyUwe Reuter, Peter J Goadsby, Michel D Ferrari, et al.The Lancet. Neurology|April 2, 2014
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trialPeter A Calabresi, Ernst-Wilhelm Radue, Douglas Goodin, et al.The New England Journal of Medicine|September 13, 2018
Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple SclerosisTanuja Chitnis, Douglas L Arnold, Brenda Banwell, et al.Pageof 2